Short communication

Are genetic variants for tobacco smoking associated with cannabis involvement?

Arpana Agrawal [a,*], Michael T. Lynskey [b], Manav Kapoor [a], Kathleen K. Bucholz [a], Howard J. Edenberg [c], Marc Schuckit [d], Andrew Brooks [e], Victor Hesselbrock [f], John Kramer [g], Nancy Saccone [h], Jay Tischfield [d], Laura J. Bierut [a]

[a] Washington University School of Medicine, Department of Psychiatry, St. Louis, MO, USA
[b] Institute of Psychiatry, Addictions Department, London, UK
[c] Indiana University School of Medicine, Indianapolis, IN, USA
[d] University of California, San Diego, CA, USA
[e] Rutgers University, Department of Genetics, Piscataway, NJ, USA
[f] University of Connecticut Health Center, Department of Psychiatry, Farmington, CT, USA
[g] University of Iowa Carver College of Medicine, Iowa City, IA, USA
[h] Washington University School of Medicine, Department of Genetics, St. Louis, MO, USA

ARTICLE INFO

ABSTRACT

Background: Cannabis users are highly likely to also be tobacco cigarette smokers and a proportion of this comorbidity is attributable to shared genetic influences. Three large meta-analyses of genomewide association studies (GWAS) of tobacco smoking have identified multiple genomewide significant ($p < 5 \times 10^{-8}$) single nucleotide polymorphisms (SNPs). We examine whether these SNPs are associated with tobacco smoking and with cannabis involvement in an independent sample.

Method: Eleven SNPs associated with cigarettes per day (CPD), ever versus never smoking and current smoking/smoking cessation at $p < 5 \times 10^{-8}$ were selected from three published meta-analyses. Association analyses were conducted with similar tobacco smoking measures in 2716 European-American subjects from the Study of Addictions Genes and Environment (SAGE) and with lifetime and current cannabis use and DSM-IV cannabis abuse/dependence.

Results: Cannabis use and tobacco smoking correlated at 0.54. Rs16969968 in CHRNA5 (and its proxy, rs1051730 in CHRNA3) and rs1451240, a proxy for rs13280604 in CHRNB3, were associated with CPD after Bonferroni correction ($p < 0.006$). rs1451240 was also associated with DSM-IV cannabis abuse/dependence. Rs6265 in *BDNF* was associated with smoking initiation, as in the original meta-analysis and also with lifetime cannabis use. Associations with cannabis involvement were no longer significant upon adjustment for the tobacco smoking measures.

Conclusions: The modest associations between cannabis involvement and SNPs for tobacco smoking were not independent of the comorbidity between tobacco and cannabis involvement. Larger samples of individuals might be required to articulate the specific genetic architecture of cannabis involvement.

© 2015 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Cannabis and tobacco smoking frequently co-occur (Grant et al., 2004). A proportion of this correlation between cannabis involvement and cigarette smoking has been attributed to genetic

influences (Agrawal et al., 2012), with genetic correlations ranging from 0.31 in an adolescent sample to 0.82 (in adults) (Huizink et al., 2010; Neale et al., 2006; Young et al., 2006). One twin study also noted that while cannabis and nicotine dependence are influenced by different genetic factors, the correlation between these factors is 0.82 (Kendler et al., 2007).

Despite evidence for genetic overlap, few studies have examined whether genetic variants implicated for one substance also influence the other. Even though cannabis and tobacco have unique pharmacological profiles, it is possible that pleiotropic effects may be responsible for shared aspects of their use and misuse,

such as experience of reward or attenuation of negative mood states. One approach for identifying such genetic variants is to focus on those that have been repeatedly identified in meta-analyses of genomewide association studies (GWAS; Duncan and Keller, 2011). As GWAS simultaneously examines a million or more single nucleotide polymorphisms (SNPs), in these analyses only SNPs with p-values of 5×10^{-8} are considered statistically significant. Consequently, the identification of such SNPs typically necessitates large sample sizes. While there have not been such meta-analyses for cannabis involvement, three large meta-analyses of cigarette smoking have identified such significant SNPs (Liu et al., 2010; Thorgeirsson et al., 2010; Tobacco and Genetics Consortium, 2010). In the present study, we selected 11 genomewide significant SNPs associated with CPD, smoking initiation and smoking cessation/current smoking and examined: (a) whether they were associated with equivalent cigarette smoking measures in European-American subjects from an independent sample, Study of Addictions Genes and Environment (SAGE); and (b) whether the same SNPs were associated with cannabis use, current use and DSM-IV cannabis abuse/dependence in SAGE, especially after accounting for comorbid cigarette smoking.

2. Methods

2.1. Sample

Data were extracted from SAGE, which drew data from three independent studies to create a sample of unrelated DSM-IV alcohol dependent cases and alcohol exposed controls (Bierut et al., 2010). Analyses focused on those of self-reported European-American ancestry who also had genotypic data ($N = 2716$).

2.2. Measures

All three parent studies (Begleiter et al., 1995; Bierut et al., 2007, 2008; Nurnberger et al., 2004) used modified versions of the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA) to assess substance use and substance use disorders (Bucholz et al., 1994). The current analyses utilized data on nicotine and cannabis related measures. For *nicotine*, these included smoking initiation (defined as smoking 100 or more cigarettes during the lifetime; while this is also referred to as regular smoking, we use the term "smoking initiation" to be consistent with prior meta-analyses of this phenotype), current tobacco use (currently using tobacco or last using a tobacco product within the year prior to the interview) and cigarettes smoked per day (CPD), defined as a categorical variable (0 = 10 cigarettes or less; 1 = 11–20; 2 = 21–30; 3 = 31 or more). Those who did not report smoking initiation were coded as missing for current smoking and CPD. For *cannabis*, items included ever using cannabis, current use (currently using cannabis or last using cannabis with the year prior to the interview) and DSM-IV cannabis abuse/dependence, with lifetime never users coded as missing for current use and abuse/dependence.

2.3. Genotyping

As described in more detail in a previous publication (Laurie et al., 2010), genotypic data were obtained from the Illumina Human 1M beadchip. For the current analyses, 11 SNPs were selected based on evidence for genomewide significant association in three large meta-analyses (Table 1).

2.4. Data analysis

Analyses were conducted using linear (CPD) and logistic (smoking and cannabis initiation, current use of cigarettes and cannabis, cannabis abuse/dependence) regression models in PLINK (Purcell et al., 2007), with genotype coded log-additively (0, 1, 2 copies of the minor allele). Covariates included sex, age at interview, source of study data and two principal components that accounted for any residual admixture in those of European-American ancestry. Only SNPs associated with a specific tobacco smoking phenotype in the original meta-analyses were tested against that phenotype (e.g., rs6265 was only tested for smoking initiation). Likewise, only SNPs associated with any tobacco smoking measure were further tested with cannabis involvement measures.

3. Results

The mean age of the sample was 38.7 [range 18–77 years]. Ever smoking even one cigarette ($N = 2447$) and ever using cannabis ($N = 2017$) was reported by 90.1% and 74.2% of the sample, respectively. Of those who had ever smoked, 84.5% reported smoking 100 or more cigarettes (smoking initiation; $N = 2067$). Current smokers ($N = 1391$) and cannabis users ($N = 622$) comprised 67.3% and 30.1% of those who had smoked 100 or more cigarettes and ever used cannabis, respectively. Of those who had ever used cannabis ($N = 2017$), 822 met criteria for DSM-IV cannabis abuse/dependence. In addition, for tobacco smoking, of those who had smoked 100 or more cigarettes, 1030, 530 and 223 individuals reported smoking ≥10, 11–20 and 21–30 CPD, respectively, with the remainder reporting smoking >30 cigarettes. Of those who had initiated smoking ($N = 2067$), 39.4% were nicotine dependent by the Fagerström Test for Nicotine Dependence criteria (≥4 symptoms).

Among those who had ever used cannabis, 96.7% ever smoked cigarettes and 90.6% reported smoking initiation ($r = 0.67$). Of those who reported current cannabis use, 85% were also current tobacco users ($r = 0.56$). CPD scores ($r = 0.47$) and FTND ($r = 0.54$) were also correlated with DSM-IV cannabis abuse/dependence.

Table 2 presents association results for the tobacco smoking and cannabis involvement measures. After correction for multiple testing, the data confirmed previously reported associations between rs6265 (*BDNF*) and smoking initiation and between rs16969968 (*CHRNA5*), rs1051730 (*CHRNA3*) and rs1451240 (*CHRNB3*) with CPD. For cannabis, rs6265 was associated with lifetime cannabis use while rs1451240 was associated with DSM-IV cannabis abuse/dependence.

To examine whether the associations for cannabis involvement were attributable to the comorbidity between smoking initiation and ever using cannabis (for rs6265) and between nicotine dependence (FTND; see Rice et al., 2012) and DSM-IV cannabis abuse/dependence (for rs1451240), analyses were repeated while including the tobacco measures as covariates. In both instances, while effect sizes remained consistent (odds-ratios for rs6265 and rs1451240 were 0.85 and 0.88 respectively), the p-values were no longer significant (p-value of 0.07 and 0.15, respectively). Regardless of adjustment for tobacco smoking, rs6265 (adjusted $R^2 = 0.003$) and rs1451240 (adjusted $R^2 = 0.004$) explained only modest proportions of variance in cannabis use and abuse/dependence respectively.

4. Discussion

These analyses suggest that the association between cannabis involvement and SNPs previously associated with tobacco smoking in three large meta-analyses is modest and, quite likely, not specific to cannabis involvement. Additionally, while the association between rs16969968/rs1051730 and tobacco smoking is well-replicated (Bierut, 2011), these SNPs were not associated with cannabis involvement (Culverhouse et al., 2014).

In contrast, our own prior study (Rice et al., 2012) has found support for the association between rs1451240 and FTND. This SNP is a proxy for rs13280604 in *CHRNB3* which was associated at genomewide significant levels ($p = 2.4 \times 10^{-8}$) with CPD in one prior meta-analysis (Thorgeirsson et al., 2010) and has been implicated in studies of nicotine dependence (Hoft et al., 2009b; Saccone et al., 2007) as well as subjective reactions to nicotine (Ehringer et al., 2010; Zeiger et al., 2008). The present study finds support for a similar protective association for the same allele of this variant and cannabis abuse/dependence. Being intronic, the functional significance of this SNP is unknown. This SNP has also been linked to alcohol consumption (Hoft et al., 2009a) indicating its putatively pleiotropic role across a host of substance-related behaviors.

Similarly, rs6265 in *BDNF*, a missense SNP (Val66Met), was associated with smoking initiation and with lifetime cannabis use. In